Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Rapid and consistent platelet inhibition is essential in the acute phase of ST-segment elevation myocardial infarction (STEMI).
• Oral P2Y12 inhibitors are recommended early for STEMI patients undergoing primary percutaneous coronary intervention (PCI).
• A delay in the onset of oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has been observed, potentially leading to inadequate platelet inhibition during primary PCI.

Purpose of the Study:

• To address the clinical challenge of delayed P2Y12 inhibitor effects in STEMI patients.
• To explore strategies for bridging the gap in platelet inhibition during the critical early hours of STEMI management.
• To enhance the effectiveness of antiplatelet therapy in patients undergoing primary PCI.

Main Methods:

• Review of current literature on P2Y12 inhibitor pharmacodynamics in STEMI.
• Analysis of strategies to optimize early platelet inhibition.
• Discussion of potential clinical benefits of bridging strategies.

Main Results:

• Oral P2Y12 inhibitors exhibit a delay in achieving adequate platelet inhibition in the initial hours post-administration.
• Primary PCI is often performed with potentially suboptimal P2Y12 inhibition.
• Several strategies exist to mitigate this delay, including upstream administration, dose modification, intravenous agents, and glycoprotein IIb/IIIa inhibitors.

Conclusions:

• Addressing the delay in P2Y12 inhibitor onset is critical for STEMI management.
• Implementing bridging strategies can ensure adequate platelet inhibition during the high-risk "golden window" of STEMI.
• These strategies hold the potential to improve clinical outcomes in STEMI patients undergoing primary PCI.